Background: Peripheral nodal follicular T-cell lymphomas expressing follicular helper T-cell (T FH ) markers have recently been identified. Such lymphomas are characterized by a nodal neoplastic T-cell proliferation accompanied by numerous reactive B cells and demonstrate some overlap with nodal angioimmunoblastic Tcell lymphoma (AITL). We identified 5 cases of cutaneous T-cell lymphoma with a peculiar pathologic aspect and expression of T FH markers.
for all patients was cutaneous T FH lymphoma. The patient with localized disease was successfully treated with radiotherapy. Patients with diffuse disease showed marked resistance to treatments, with only 1 case of complete remission after allogeneic hematopoietic stem cell transplantation followed by bortezomib and donorlymphocyte infusion. Bexarotene, methotrexate, thalidomide, interferon alfa, gemcitabine, liposomal doxorubicin, or multiagent chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) were either ineffective or induced transitory partial remission.
Conclusions:
We describe an original clinicopathologic series of primary cutaneous lymphomas with T FH phenotype, suggesting the existence of a new entity among cutaneous T-cell lymphomas. Relations of these lymphomas with the provisional entity of primary cutaneous small to medium CD4 ϩ pleomorphic T-cell lymphoma need to be further addressed.
Arch Dermatol. 2012;148 (7) :832-839. Published online April 16, 2012 April 16, . doi:10.1001 April 16, /archdermatol.2011 F OLLICULAR HELPER T (T FH ) cells are a specific subset of CD4 ϩ helper T cells (T H ), normally found in the germinal centers of B-cell follicles. 1 They provide help to B cells and cause them to differentiate into long-lived, antibodysecreting plasma cells or memory B cells. 2, 3 T FH cells have been distinguished from subtypes T H 1 and T H 2 by several criteria, including a peculiar expression of CXCR5, CXCL13, CD10, Bcl-6, PD-1, and ICOS. 4 Gene expression profiling of nodal peripheral T-cell lymphoma (PTCL) demonstrated that neoplastic T cells in angioimmunoblastic T-cell lymphoma (AITL) derive from T FH cells. 5 Neoplastic T-cells in AITL indeed express CD10, Bcl-6, ICOS, CXCL13, and PD-1. [6] [7] [8] [9] More recently, a subset of nodal PTCL with follicular growth (follicular PTCL), derived from T FH cells, has been identified among PTCL unspecified (PTCL-NOS). [10] [11] [12] [13] [14] These lymphomas have been shown to express T FH markers (CD10, Bcl-6, PD-1, CXCL13, and ICOS) and may show overlapping features with AITL.
14 Twenty-six percent of patients reported to date were said to have systematic nodal involvement and skin involvement. In 2010, 2 cases of primary cutaneous follicular variant of PTCL were reported, in which histopathologic features were reminiscent of those found in nodal follicular PTCL, with no detailed clinical data. 15 We report herein an original series of 5 primary cutaneous T-cell lymphomas with expression of T FH markers. We pro-pose calling them primary cutaneous T FH lymphomas, and discuss their relationship to the existing entities of the latest World Health Organization (WHO) classification of lymphomas, especially the provisional entity of primary cutaneous CD4
ϩ small-to medium-sized pleomorphic T-cell lymphoma (PCSMTCL). 16, 17 
REPORT OF CASES

CLINICAL, BIOLOGICAL, AND IMAGING FINDINGS
Clinical data and evaluation of the extension of the disease are shown in Table 1 . In brief, patients 1 to 4 had very similar clinical presentation, consisting of multiple papules, plaques, and nodules, distributed on the trunk (in 4 of the 4), the limbs (in 3 of the 4), and the head and neck region (in 3 of the 4). The lesions were erythematous to violaceous and more or less infiltrated (Figure 1) . Some of them showed clinical edema. Lesions were not ulcerated. The lesions had appeared progressively over few months, without any history of previous chronic patch or plaque stage. Patient 5 showed a solitary erythematous infiltrated plaque 5 cm in diameter on the right cheek, with nodular reinforcement, evolving over a few months.
Patients 1 and 2 developed palpable regional adenopathies 1 year and 4 years, respectively, after initial skin lesions (axillar or cervical). The patients had no systemic symptoms. Notably, B-cell lymphoma symptoms were absent. Biologic tests showed elevated lactate dehydrogenase in 1 case (patient 3), moderate lymphopenia (700 lymphocytes/µL) in patient 1, and eosinophilia (1800 eosinophils/µL) in patient 4. Other results were in the normal range.
Imaging studies for evaluation of the extension of the disease consisted in thoraco-abdomino-pelvic computed tomography (TAP-CT) in all cases, and positron emission tomography-computed tomography (PET-CT) in patient 3. They did not reveal any visceral involvement nor deepseated adenopathies. In patient 3, PET-CT showed only diffuse hypermetabolic cutaneous lesions.
The patients' medical history was nonremarkable, except for non-Langerhans cell cutaneous histiocytosis in patient 4, diagnosed 6 years prior to the cutaneous lymphoma, for which he had been treated with psoralen-UV-A (PUVA) therapy. Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; DLI, donor lymphocyte infusion; HSC, hematopoietic stem cell; LDH, lactate dehydrogenase; ND, not done; PET, positron emission tomography; R-CVP, rituximab-cyclophosphamide, vincristine, and prednisone; R-CHOP, rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone; TAP-CT, thoraco-abdomino-pelvic computed tomography.
a Delay of onset after the skin lesions. b Visceral disease extension.
HISTOPATHOLOGIC FINDINGS
In all patients, initial skin biopsies performed either on nodular and/or plaque-type lesions showed similar findings ( Figure 2 ). Findings from biopsy specimens from nodular lesions showed a diffuse dense dermal lymphoid infiltrate, with no epidermotropism. In 2 cases, there was slight pilotropism with focal follicular mucin deposits. Biopsies of plaque-type lesions showed a subepidermal, bandlike lymphoid infiltrate, with no epidermotropism, and a grenz-zone between the infiltrate and the epidermis. The infiltrate was made up of about 50% of CD3 ϩ T cells and 50% of CD20 ϩ B cells. The B-and Tcell populations were admixed without clear B-or Tcell zone (Figure 3) . The infiltrate contained a subset of atypical medium to large lymphoid cells showing irregular nuclei with finely dispersed chromatin and small nucleoli, on a background of small lymphocytes and rare eosinophils. Some immunoblast-like cells were also seen. Immunohistochemical stains showed Bcl-6 expression (in all 5 patients) and frequent CD10 expression (in 4 of 5) in the infiltrate. Owing to CD10 and Bcl-6 expression in the lymphoid infiltrate and to the important B-cell population, patients 1 to 3 were initially misdiagnosed as having primary cutaneous follicle-center B-cell lymphoma (PCF-BCL). However, they were unresponsive to rituximabcontaining (R) chemotherapies (respectively, R-CHOP; rituximab; and rituximab-cyclophosphamide, vincristine, and prednisone). After treatment with rituximab, skin biopsies were performed in these 3 cases, showing a diffuse dermal infiltrate of medium to large atypical CD3 ϩ , CD4 ϩ , and CD8 − T cells, with no CD20 and no CD79a B-cells, precluding the initially proposed diagnosis of PCFBCL, and suggesting T-cell lymphoma. In these biopsy specimens, atypical T cells expressed CD10 and Bcl-6, which was evocative of T FH phenotype.
Additional immunostainings for CXCL-13, PD-1, ICOS, and Ki-67 were performed on all biopsy specimens. The proliferative index was moderately high, varying from 30% to 50% in the same patient. Test results for in situ hybridization for Epstein-Barr virus-encoded small RNAs (EBER) were consistently negative. CD30 expression was restricted to rare B immunoblasts.
In patients with palpable adenopathies, lymph node biopsies were performed at least twice. The lymph nodes were hyperplastic, and none showed areas suspect for Tcell lymphoma on morphologic and immunohistochemical analyses, including Bcl-6, CD10, PD-1, CXCL13, and ICOS staining.
Overall, the histopathologic aspect was evocative of T-cell lymphoma, with peculiar important B-cell reactive component, and expression of T FH markers. Therefore, we propose classifying these cases as primary cutaneous T FH lymphoma.
CLONALITY ANALYSIS
The results are shown in Table 2 . In brief, T-cell clonality was found in all skin biopsy specimens. The same Tcell clone was found in circulating lymphocytes in the 4 cases with diffuse lesions. When lymph node biopsy was performed, lymph node T-cell clone was either not found (patient 1) or minor (patient 2). Bone marrow T-cell clonality was looked for and found in 2 cases. Interestingly, patient 1 initially showed an associated B-cell clone in the skin and the blood. After R-CHOP therapy, this clone disappeared on following biopsy specimens and blood samples.
TREATMENTS AND FOLLOW-UP DATA.
The mean duration of follow-up was 47.8 months (range, 19-85 months). Patient 5, who had local disease, was treated with radiotherapy and is in complete remission to date (19 months). Overall, patients 1 to 4 showed relative resistance to treatments and required systemic chemotherapies. Patient 1 was successively treated with topical steroids, PUVA therapy, interferon alfa, bexarotene, methotrexate, gemcitabine hydrochloride, and liposomal doxorubicin. Only gemcitabine resulted in partial remission of the disease, with early recurrence after interruption of the treatment. To date, he is still being treated with gemcitabine (as of the 49-month followup). Patient 2 was successively treated with thalidomide, interferon alfa, and CHOP (6 cycles). CHOP allowed partial remission, and the patient's disease has been stabilized for 10 months to date by using bexarotene as maintenance therapy. To date, he too is still being treated with gemcitabine (as of the 85-month follow-up). Patient 3 was successively treated with CHOP; dexamethasone, cytarabin, and cisplatin (DHAP); and autologous hematopoietic stem cell transplantation (HSCT). Both treatments resulted in transitory complete remission with early recurrence. He underwent therapy with allogeneic HSCT, which was followed by an early relapse after 2 months. Bortezomib and donor-lymphocyte infusion resulted in complete and prolonged remission after 20 months of treatment (as of the 61-month follow-up). Patient 4 was successively treated with topical nitrogen mustard, topical carmustin, methotrexate, bexarotene, and localized radiotherapy on a tumor. He is now in partial remission (as of the 25-month follow-up).
COMMENT
We report herein a unique clinicopathologic series of primary cutaneous T-cell lymphomas with expression of T FH markers. These cases are characterized by similar histopathologic features, with a diffuse dermal lymphoid infiltrate with admixed T and B cells in relatively equal proportions, the presence of atypical medium-to-large lymphoid cells in variable proportions, absence of epidermotropism, and expression of T FH markers. Patients 1 to 4 shared a remarkable clinical picture of multiple diffuse papules, small plaques, and nodules, predominating on the trunk, the limbs, and the head and neck, with no systemic symptoms, and unaltered performance status. Although T-cell clonality was found in the blood and in the bone marrow, and although the lesions were relatively resistant to current therapies for cutaneous Tcell lymphomas, the patients displayed an indolent course, with no deaths after almost 5 years of follow-up.
Neoplastic T cells in our cases expressed at least 2 of the following T FH markers: CD10, Bcl-6, CXCL13, PD-1, or ICOS. CXCL13 and Bcl-6 are among the genes whose 
Thalidomide, interferon alfa, rituximab
Abbreviations: B, B cells; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; EBER, Epstein-Barr virus-encoded small RNAs; LN, lymph node; ND, not done; R-CVP, rituximab-cyclophosphamide, vincristine, prednisone; T, T cells; −, negative; ϩ, positive.
ARCH DERMATOL/ VOL 148 (NO. 7), JULY 2012 WWW.ARCHDERMATOL.COM 837 expression is most highly upregulated in T FH cells. 18 Programmed cell death 1 (PD-1) is an inhibitory member of the CD28 family, mainly expressed in activated T cells, and especially in T FH cells. 4 Expression of PD-1 has been reported in mycosis fungoides, Sézary syndromes and in adult T-cell leukemia and lymphoma.
19,20 CD10 expression can be found in some cases with PCFBCL and has been reported in a subset of epithelial and soft-tissue tumors. Bcl-6 is expressed in PCFBCL and in some diffuse large B-cell lymphomas. 17 ICOS expression in lymphomas seems restricted to AITL and follicular T-cell lymphoma. 21 None of the 5 T FH markers in this study is entirely specific for T FH lineage, and none can be used alone to ascertain a diagnosis of T FH lymphoma. To prove T FH differentiation, the expression of a combination of various T FH markers should be demonstrated, as has been performed in previous studies. 14, 22 Some differential diagnoses could have been discussed. Mycosis fungoides has been ruled out because of the lack of concordant clinical anamnesis and because of the T FH phenotype of the pleomorphic T cells. The prominent B-cell component and lack of epidermotropism were other arguments against MF, though both may rarely be encountered in MF. PCFBCL can be a diagnosis pitfall, owing to the important B-cell component, to the presence of blastlike B cells, and to the expression of the usual follicular B-cell markers CD10 and Bcl-6. However, careful examination in our cases revealed large, atypical T cells expressing CD10 and Bcl-6, and patients treated with rituximab showed no clinical response.
Nodal follicular PTCL, a variant of PTCL NOS, has overlapping features with AITL (ie, hypergammaglobulinemia, eosinophilia, positive Coombs test result, multiple adenopathies, splenomegaly, B symptoms, and some histopathologic features).
14 Classic AITL is characterized by 44% of cutaneous involvement, consisting in a maculopapular eruption, with a waxing and waning course, and a patchy perivascular polymorphic lymphoid infiltrate with expression of CXCL13. 6, 23 T-cell clonality has been found in 96% of cases, with possible associated B-cell clonality in 45%. 24 AITL is almost always associated with Epstein-Barr virus infection, in contrast with our cases, in which test results for EBER were consistently negative. Clinical presentation in our cases was also different from cutaneous AITL, in that it lacked the waxing and waning course; was mostly papulonodular; and was isolated, without systemic symptoms, multiple adenopathies, effusions, arthritis, or splenomegaly. Although some features were reminiscent of AITL (ie, neoplastic clear cells, scattered B immunoblasts, expression of T FH markers, presence of a B clonality [patient 1], eosinophilia [patient 4], overall clinicopathologic presentation) was not in favor of AITL stricto sensu.
Another differential diagnosis in these cases is primary cutaneous small to medium CD4 ϩ T-cell lymphoma (PCSMCTL), considered as a provisional entity in the 2008 WHO classification of lymphomas. 16, 17 Histopathologically, PCSMCTL is primarily a diagnosis of exclusion. It shows a dense, diffuse, or nodular infiltrate within the dermis, with a predominance of smallto medium-sized pleomorphic T cells. A considerable admixture with small reactive lymphocytes, CD20 ϩ blasts, eosinophils, plasma cells, and histiocytes may be observed. By definition, the cells have a CD3 − phenotype, without cytotoxic granules, and show clonal rearrangement of T-cell receptor gene. Recent studies have shown that PCSMCTL is clinically highly heterogeneous, encompassing many cases with localized disease and benign evolution, and rarer diffuse cases with poor prognosis. 25 Contradictory results have been published regarding the expression of T FH markers in PCSMCTL. T FH markers were positive in the study by Rodríguez Pinilla et al, 22 whereas CD10 and Bcl-6 were consistently negative in the study by Grogg et al 26 Altogether, it seems that the provisional entity of PCSMCTL may encompass different subtypes of T-cell lymphomas, not yet recognized. The PCSMCTL entity should be rethought in the next few years. Cases described herein as primary cutaneous T FH lymphoma may represent a part of PCSMCTL or may have partial overlap with this provisional entity. In particular, patient 5 had a clinical presentation close to the classic one of PCSMCTL, differing only by the prominence of medium to large T cells and by their T FH phenotype. The presentation of our patients with diffuse disease may better fit in the category of PTCL NOS.
In conclusion, we describe herein an original series of 5 primary cutaneous T-cell lymphomas with expression of T FH markers, which could be called primary cutaneous T FH lymphomas. Table 3 shows provisional criteria that we propose for these lymphomas, which could represent the cutaneous counterpart of the nodal follicular PTCLs, a variant of PTCL NOS. 
